Form 4: Cidara Therapeutics Acquired by Merck for $221.50/Share

Cidara Therapeutics, Inc. director Chrysa Mineo reports disposition of shares and options following its acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its wholly-owned subsidiary, Caymus Purchaser, Inc., following a tender offer.
• The merger was completed on January 7, 2026, resulting in Cidara Therapeutics, Inc. becoming a wholly-owned subsidiary of Merck.
• Common Shares were acquired for $221.50 per share in cash, without interest and subject to applicable withholding taxes.
• Series A Convertible Voting Preferred Stock was acquired for $15,505.00 per share in cash, without interest and subject to applicable withholding taxes.
• Director Chrysa Mineo disposed of 3,320 shares of common stock at $221.50 per share.
• All outstanding stock options held by the director became fully vested and exercisable immediately prior to the merger's effective time, then were cancelled for cash consideration.
• The cash consideration for options was calculated as the product of the total number of common shares subject to the option multiplied by the excess of the $221.50 merger price over the option's exercise price.
• The exercise prices and number of securities for options were adjusted to reflect a 1-for-20 reverse stock split effected by Cidara Therapeutics, Inc. on April 24, 2024.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger where Cidara Therapeutics was acquired by Merck, providing a significant cash payout to shareholders and option holders. This represents a positive liquidity event and value realization for the reporting person and other shareholders.

Positives

• Shareholders received a significant cash payment of $221.50 per Common Share and $15,505.00 per Series A Share, providing a clear return on investment.
• Stock options held by the director became fully vested and were converted into cash, allowing for the realization of their intrinsic value.
• The acquisition by a major pharmaceutical company like Merck suggests a successful strategic outcome for Cidara's assets and technology.

Negatives

• Cidara Therapeutics, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Merck.
• The reporting person, Chrysa Mineo, no longer beneficially owns common stock or derivative securities of Cidara Therapeutics, Inc.

Risks

• The filing is a post-merger transaction report and does not detail ongoing operational or financial risks for the acquired entity or the acquirer. The primary 'risk' for former shareholders is the cessation of future equity upside from Cidara as an independent entity.

Future Outlook

The filing does not provide a future outlook for Cidara Therapeutics, Inc. as it has been acquired and is now a wholly-owned subsidiary of Merck. The focus is on the completed transaction and the disposition of securities.

Industry Context

The acquisition of Cidara Therapeutics by Merck Sharp & Dohme LLC reflects a continuing trend of larger pharmaceutical companies acquiring smaller biotechnology firms to bolster their pipelines, gain access to innovative technologies, or eliminate competition. This particular transaction indicates Merck's strategic interest in Cidara's assets, likely in its infectious disease or oncology programs, which are key areas of focus for major pharmaceutical players.

Comparison to Industry Standards

• The acquisition price of $221.50 per common share represents a premium typically seen in strategic acquisitions within the biotechnology sector, especially when a major pharmaceutical company like Merck is the acquirer.
• Similar acquisitions in the biotech space, such as Pfizer's acquisition of Seagen for $43 billion or AbbVie's acquisition of ImmunoGen for $10.1 billion, demonstrate the high valuations placed on promising therapeutic assets and platforms.
• The conversion of stock options into cash at the merger price minus the exercise price is a standard practice in M&A transactions, ensuring that option holders realize the intrinsic value of their equity awards.

Stakeholder Impact

• Shareholders: Received a cash payout for their shares, realizing value from their investment.
• Employees: Cidara Therapeutics employees are now part of Merck, potentially impacting their roles, benefits, and corporate culture.
• Customers/Partners: Cidara's existing customers or partners will now interact with a Merck subsidiary, potentially leading to changes in product development or service delivery.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck.
• Former shareholders of Cidara Therapeutics, Inc. will receive their cash consideration for tendered shares and converted options.

Key Dates

Recommendation

The company has been acquired, and its shares are no longer publicly traded. The transaction is complete, and shareholders have received cash consideration. Therefore, there is no longer an opportunity to 'buy' or 'hold' the stock, and any remaining shares would have been tendered or converted, effectively a 'sell' for the purpose of realizing value.

Keywords

Cidara Therapeutics, Merck, Acquisition, Merger, Tender Offer, CDTX, Form 4, Insider Transaction, Stock Options, Biotechnology, Pharmaceuticals